newsfilter
← Latest News
GlobeNewswire·

MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress

  • Completed Phase 1 dose escalation for MGC028 ADC targeting ADAM9 1 selected lead indication 2 plans randomized evaluation of two dose levels by end of 2026 with no dose-limiting toxicities or ILD/ocular toxicity reported as of October 10 2026
  • Reported interim Phase 1 results for MGC026 B7-H3 ADC at ESMO 2026 showing encouraging efficacy in heavily pretreated SCCHN patients 1 expects to complete enrollment of the 40-patient monotherapy cohort by year-end 2026
  • Dosed first patient in Phase 1 study for MGC030 first-in-class ADC targeting an undisclosed antigen across multiple solid tumor types
  • Reported interim Phase 2 results for lorigerlimab PD-1 x CTLA-4 bispecific at ESMO 2026 demonstrating clinical activity in clear cell gynecologic cancer 1 expects to complete enrollment of 20 patients at a lower dose by year-end 2026
  • Strengthened Board with appointment of two new independent directors Emil Kuriakose 1 M.D. 1 2 Michael Vasconcelles 1 M.D. 1 both with oncology drug development expertise
  • Gilead Sciences exercised option to license a preclinical bispecific program triggering a $10.0 million payment to MacroGenics
  • Cash 1 cash equivalents 1 2 marketable securities totaled $287.7 million as of September 30 2026 1 with cash runway guidance extending through 2028
  • Received $119.6 million from Bora for sale of GMP manufacturing operations 1 $24.5 million regulatory milestone from Sanofi 1 2 $10.0 million option license payment from Gilead during the quarter
  • Reported total revenue of $18.7 million for the quarter ended September 30 2026 1 down from $53.0 million in the prior year quarter primarily due to lower milestone revenue
  • Research 1 2 development expenses were $30.6 million for the quarter 1 down from $32.7 million in the prior year quarter 1 driven by lower costs for lorigerlimab 1 vobramitamab duocarmazine 1 2 MGC030 partially offset by increased clinical costs for MGC026 1 MGC028 1 2 MGC030
  • General 1 2 administrative expenses decreased to $8.4 million from $9.9 million in the prior year quarter 1 primarily due to lower personnel-related costs
  • Reported a net loss of $20.1 million for the quarter ended September 30 2026 1 compared to net income of $16.8 million in the same period last year
  • Shares of common stock outstanding were 63,875,835 as of September 30 2026
Company
MacroGenics, Inc.
Keywords
Nasdaq:MGNX, MacroGenics, Inc.